Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy

Michael P. Sanderson, Marco H. Hofmann, Pilar Garin-Chesa, Norbert Schweifer, Andreas Wernitznig, Stefan Fischer, Astrid Jeschko, Reiner Meyer, Jürgen Moll, Thomas Pecina, Heribert Arnhof, Ulrike Weyer-Czernilofsky, Stephan K. Zahn, Günther R. Adolf, Norbert Kraut

Mol Cancer Ther (2017) 16 (10): 2223–2233.

DOI: https://doi.org/10.1158/1535-7163.MCT-17-0336

Published: 02 October 2017

View article

Includes: Supplementary data

Journal Articles

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

Mol Cancer Ther (2016) 15 (10): 2388–2398.

DOI: https://doi.org/10.1158/1535-7163.MCT-16-0066

Published: 02 October 2016

View article

Includes: Supplementary data

Journal Articles

A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation

Irene C. Waizenegger, Anke Baum, Steffen Steurer, Heinz Stadtmüller, Gerd Bader, Otmar Schaaf, Pilar Garin-Chesa, Andreas Schlattl, Norbert Schweifer, Christian Haslinger, Florian Colbatzky, Sien Mousa, Arno Kalkuhl, Norbert Kraut, Günther R. Adolf

Mol Cancer Ther (2016) 15 (3): 354–365.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0617

Published: 06 March 2016

View article

Includes: Supplementary data

Journal Articles

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

Michael P. Sanderson, Joshua Apgar, Pilar Garin-Chesa, Marco H. Hofmann, Dirk Kessler, Jens Quant, Alexander Savchenko, Otmar Schaaf, Matthias Treu, Heather Tye, Stephan K. Zahn, Andreas Zoephel, Eric Haaksma, Günther R. Adolf, Norbert Kraut

Mol Cancer Ther (2015) 14 (12): 2762–2772.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0539

Published: 06 December 2015

View article

Includes: Supplementary data

Journal Articles

Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.

Ulrich A. Hirt, Juergen Braunger, Michael Schleicher, Ulrike Weyer-Czernilofsky, Pilar Garin-Chesa, Bojan Bister, Heinz Stadtmueller, Ioannis Sapountzis, Norbert Kraut, Guenther R. Adolf

Mol Cancer Ther (2011) 10 (11_Supplement): A249.

DOI: https://doi.org/10.1158/1535-7163.TARG-11-A249

Published: 12 November 2011

View article

Journal Articles

Expression and Targeting of Human Fibroblast Activation Protein in a Human Skin/Severe Combined Immunodeficient Mouse Breast Cancer Xenograft Model

Kiki Tahtis, Fook-Thean Lee, Jennifer M. Wheatley, Pilar Garin-Chesa, John E. Park, Fiona E. Smyth, Yuichi Obata, Elisabeth Stockert, Cathrine M. Hall, Lloyd J. Old, Wolfgang J. Rettig, Andrew M. Scott

Mol Cancer Ther (2003) 2 (8): 729–737.

Published: 25 August 2003

View article

NARROW

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.

Expression and Targeting of Human Fibroblast Activation Protein in a Human Skin/Severe Combined Immunodeficient Mouse Breast Cancer Xenograft Model

Email alerts

AACR Journals

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy

Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation

BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis

Abstract A249: BI 853520, a potent and highly selective inhibitor of protein tyrosine kinase 2 (focal adhesion kinase), shows efficacy in multiple xenograft models of human cancer.

Expression and Targeting of Human Fibroblast Activation Protein in a Human Skin/Severe Combined Immunodeficient Mouse Breast Cancer Xenograft Model

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only